Clinical trials: Multidrug Resistant Bacterial Infection
Bacterial Contamination
The Effectiveness of Antimicrobial Breathing System on the Presence of Multidrug-resistant Organisms
The aim of this study is to investigates the effectiveness of antimicrobial breathing system on multidrug-resistant organisms (MDRO).
- Trial name
- NCT04927806
- Testing
- Silver Knight
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Fu Jen Catholic University
Pneumonia - Bacterial, Urinary Tract Infection Bacterial
Clinical Impact of a Machine Learning Decision Support System for Empirical Antibiotic Therapy
The goal of this quasi-experimental study is to analyze if a Machine Learning Clinical Decision Support System can improve the empirical antibiotic treatment in patients with pneumonia, urinary tract infection and / or sepsis.
- Conditions
- Pneumonia - Bacterial, Urinary Tract Infection Bacterial, Bloodstream Infection
- Trial name
- NCT07762378
- Testing
- Machine Learning Decision Support System
- Volunteers
- 486 people
- Sponsor
- Instituto de Investigación Sanitaria Gregorio Marañón
Multidrug Resistant Tuberculosis
Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide
Multidrug resistant tuberculosis (MDR-TB) is difficult to treat and raises a great challenge to TB control program. That pyrazinamide can shorten the course of treatment and facilitate bacilli clearance has been proved recently.
- Trial name
- NCT02120638
- Testing
- Pyrazinamide containing regimen, Regimen without Pyrazinamide
- Where
- 11 sites in China
- Volunteers
- 100 people
- Sponsor
- Huashan Hospital
Urinary Tract Infections, Recurrent Urinary Tract Infections
WMT for Multidrug-Resistant Organism UTI
This is a single-center, prospective, single-arm, exploratory clinical study to evaluate the efficacy, safety, and potential mechanisms of washed microbiota transplantation (WMT) in patients with recurrent urinary tract…
- Conditions
- Urinary Tract Infections, Recurrent Urinary Tract Infections, Multidrug-Resistant Bacterial Infections, Bacteriuria
- Trial name
- NCT07816913
- Testing
- Washed Microbiota Transplantation (WMT)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Tuberculosis, Multidrug-Resistant
A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683
A phase 2, multicenter, uncontrolled, open-label trial in participants with Multi-drug Resistant Tuberculosis (MDR-TB). Only participants who completed Trial 242-07-204 (NCT00685360) were eligible.
- Trial name
- NCT02573350
- Testing
- Delamanid, OBR
- Where
- 8 sites in China, Estonia and 4 more
- Volunteers
- 213 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
MDR Tuberculosis, Resistance to Tuberculostatic Drugs
Artificial Inteligent for Diagnosing Drug-Resistant Tuberculosis
Title: Artificial Neural Network as Diagnostic Tools For Rifampicin-Resistant Tuberculosis In Indonesia. A Predictive Model Study and Economic Evaluation.
- Trial name
- NCT04208789
- Testing
- Rapid Molecular Drug-Resistant Tuberculosis Test, Artificial Intelligent Model, Drug Susceptibility Test
- Where
- 5 sites in Indonesia
- Volunteers
- 524 people
- Sponsor
- Hasanuddin University
Tuberculosis, Multi-Drug Resistant Tuberculosis
Metronidazole for Pulmonary Tuberculosis (South Korea)
This study will evaluate the effect of adding metronidazole to standard second-line therapy for tuberculosis in patients who have multi-drug resistant tuberculosis (MDR-TB) of the lungs.
- Trial name
- NCT00425113
- Testing
- Metronidazole, Blood Draw, CT Scan
- Where
- 2 sites in South Korea
- Volunteers
- 35 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multidrug-Resistant Tuberculosis, Isoniazid Resistant Pulmonary Tuberculosis
Line Probe Assay Evaluation Study
This is a multi-center, blinded study to determine the performance of the YD Diagnostic Corporation (YD) REBA MTB-MDR® and Hain Genotype MTBDRplus V2 kit in a total of 600 clinical isolates and 900 residual sputum samples from…
- Conditions
- Multidrug-Resistant Tuberculosis, Isoniazid Resistant Pulmonary Tuberculosis, Rifampicin Resistant Tuberculosis, Pulmonary Tuberculoses
- Trial name
- YD (NCT02984579)
- Testing
- YD REBA MTB-MDR, Hain Genotype MTBDRplus V1, Hain Genotype MTBDRplus V2
- Volunteers
- 888 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant
A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)
This is a clinical trial to evaluate the safety and efficacy of OPC-67683 in the treatment of multidrug resistant tuberculosis (MDR TB) for 56 days.
- Conditions
- Tuberculosis, Pulmonary, Tuberculosis, Multidrug Resistant, Extensively Drug-Resistant Tuberculosis
- Trial name
- NCT00685360
- Testing
- Delamanid, Optimized Background Regimen (OBR)
- Where
- 17 sites in United States, China and 7 more
- Volunteers
- 481 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Multidrug-Resistant Gram-Negative Bacterial Infections, Antimicrobial Resistance
The Effect of Adjunctive Melatonin With Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections
This study evaluates whether adding melatonin to standard colistin therapy improves outcomes in patients with multidrug-resistant (MDR) Gram-negative bacterial infections.
- Trial name
- NCT07503600
- Testing
- Melatonin
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
MDR TB
Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB
Multidrug-resistant tuberculosis (MDR-TB) has emerged as a challenge worldwide. Few studies have prospectively reported outcomes in patients with pulmonary MDR-TB treated with adjunctive immunotherapy combined to standard…
- Trial name
- rhIL-2 (NCT03069534)
- Testing
- RhIL-2
- Where
- China
- Volunteers
- 500 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Tuberculosis, Tuberculosis, Multidrug-Resistant
Tuberculosis in China
Background: In spite of well-researched treatments and therapies, 5 to 10 percent of tuberculosis (TB) patients who have initially successful TB treatments will relapse, usually within a year after completion of therapy.
- Conditions
- Tuberculosis, Tuberculosis, Multidrug-Resistant, Extensively Drug Resistant Tuberculosis
- Trial name
- NCT01071603
- Where
- China
- Volunteers
- 199 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
A Multidrug-resistant (MDR) and Extensively Drug- Resistant (XDR) Tuberculosis Study in Alsace
The purpose of this study is to examine the epidemiology of TB MR in Strasbourg and evaluate the second-line anti-tuberculosis treatments effectiveness, and the relevance and adequacy of the treatments with WHO recommendations.
- Trial name
- NCT03507816
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Strasbourg, France
Tuberculosis, Multidrug-Resistant
A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
The purpose of this study is to evaluate efficacy and safety of an oral bedaquiline-containing multidrug-resistant tuberculosis (MDR-TB) short-course regimen (SCR) compared to an oral SCR not including bedaquiline at the end of…
- Trial name
- PROSPECT (NCT05306223)
- Testing
- Bedaquiline, Levofloxacin, Linezolid
- Where
- 17 sites in China
- Volunteers
- 212 people
- Sponsor
- Beijing Chest Hospital
Tuberculosis, Multidrug-Resistant
Hotspots, Households and Hospitals: Enhanced Drug-resistant Tuberculosis Case Finding in Namibia
Poor case management, pharmacokinetic variability and on-going transmission have fostered the drug-resistant tuberculosis (DR-TB) epidemic leading to a global estimated number of >500,000 new multidrug resistant (MDR) TB cases…
- Trial name
- H3TB (NCT05022238)
- Where
- Namibia
- Volunteers
- 2,100 people
- Sponsor
- University of Namibia
Multidrug-Resistant Tuberculosis, Rifampicin-resistant Tuberculosis
Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety, tolerability, and preliminary efficacy of acetohydroxamic acid (AHA) capsules combined with short-course…
- Conditions
- Multidrug-Resistant Tuberculosis, Rifampicin-resistant Tuberculosis, MDR-TB, RR-TB
- Trial name
- AHA-PLUS (NCT07393438)
- Testing
- Acetohydroxamic Acid
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Infection Due to Resistant Organism
FMT for MDRO Colonization After Infection in Renal Transplant Recipients
Transplant patients are at increased risk of colonization and infection with Multidrug Resistant Organisms (MDROs) due to medications that modify their immune systems, increased healthcare and antibiotic exposure, and surgical…
- Trial name
- PREMIX (NCT02922816)
- Testing
- Fecal Microbiota Transplant (FMT), Bowel preparation, Stool or perirectal swab sampling
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Resistant Infection, Antibiotic Resistant Infection
Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria
This study evaluates the impact of rank of Beta lactam antibiotics on emergence of mutlidrug resistant bacteria colonization in intensive care It's retrospective case controle study.
- Conditions
- Resistant Infection, Antibiotic Resistant Infection, Beta Lactam Resistant Bacterial Infection, Bacterial Resistance
- Trial name
- INOR Blact (NCT03752476)
- Testing
- number of Beta lactam class prescription for the same infection
- Volunteers
- 1,300 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Tuberculosis, HIV
Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV
Dzherelo (Immunoxel) is an oral immunomodulating botanical agent available over-the-counter in Ukraine. After many years of laboratory and clinical testing the formulation was approved in 1997 by the Ministry of Health of Ukraine…
- Trial name
- NCT01061593
- Testing
- Immunoxel
- Where
- 2 sites in Mongolia, Ukraine
- Volunteers
- 269 people
- Sponsor
- Lisichansk Regional Tuberculosis Dispensary
Linezolid, Tuberculosis Multi Drug Resistant Active
Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global public health. Globally, the World Health Organization (WHO) estimates the number at 400,000 patients with MDR-TB for 2023.
- Conditions
- Linezolid, Tuberculosis Multi Drug Resistant Active, Therapeutic Drug Monitoring (TDM)
- Trial name
- PLOT-TB (NCT07477119)
- Testing
- Linezolid dose personalization based on TDM
- Where
- Guinea
- Volunteers
- 150 people
- Sponsor
- Marco Schiuma